FADD adaptor in cancer.
FADD (Fas Associated protein with Death Domain) is a key adaptor molecule transmitting the death signal mediated by death receptors. In addition, this multiple functional protein is implicated in survival/proliferation and cell cycle progression. FADD functions are regulated via cellular sublocalization, protein phosphorylation, and inhibitory molecules. In the present review, we focus on the role of the FADD adaptor in cancer. Increasing evidence shows that defects in FADD protein expression are associated with tumor progression both in mice and humans. Better knowledge of the mechanisms leading to regulation of FADD functions will improve understanding of tumor growth and the immune escape mechanisms, and could open a new field for therapeutic interventions.
Tourneur
Léa
L
Département d'Immunologie, Institut Cochin, INSERM U 567, CNRS UMR 8104, IFR 116, Université René Descartes, Paris V, Paris, France. chiocchia@cochin.inserm.fr.
Buzyn
Agnès
A
Chiocchia
Gilles
G
Nat Med. 2000 Aug;6(8):920-3
10932231
Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10488-92
7937980
Nature. 1997 Jul 10;388(6638):190-5
9217161
Blood. 1997 Dec 15;90(12):4901-9
9389707
J Clin Endocrinol Metab. 1999 Aug;84(8):2924-32
10443700
Cell. 1995 May 19;81(4):505-12
7538907
Mol Cell Biol. 1996 Jun;16(6):2756-63
8649383
Science. 1998 Mar 20;279(5358):1954-8
9506948
J Immunol. 2003 Jul 1;171(1):247-56
12817005
Cancer Res. 2004 Nov 1;64(21):8101-8
15520222
Oncogene. 2003 May 8;22(18):2795-804
12743602
Nat Med. 1996 Dec;2(12):1361-6
8946836
J Clin Invest. 1997 Mar 15;99(6):1173-8
9077524
Cell Death Differ. 2003 Jul;10(7):791-7
12815462
Nature. 1992 Mar 26;356(6367):314-7
1372394
Nat Med. 2000 May;6(5):493-5
10802692
Immunity. 2003 Apr;18(4):513-21
12705854
Mod Pathol. 1998 Apr;11(4):369-75
9578088
Carcinogenesis. 2004 Jul;25(7):1089-97
15001534
Nature. 1997 Apr 3;386(6624):517-21
9087414
Cell. 1997 Feb 7;88(3):355-65
9039262
J Immunol. 2000 May 15;164(10):5023-7
10799856
J Immunol. 1996 Dec 15;157(12):5461-6
8955195
Nat Immunol. 2003 May;4(5):404-9
12719729
J Biol Chem. 2000 Aug 18;275(33):25065-8
10862756
Int J Biochem Cell Biol. 1999 May;31(5):533-7
10399313
J Biol Chem. 1998 Feb 20;273(8):4345-9
9468483
Curr Biol. 2001 Feb 20;11(4):273-6
11250157
J Exp Med. 1996 Sep 1;184(3):1075-82
9064324
Trends Biochem Sci. 2001 Aug;26(8):475-81
11504623
Int J Cancer. 2003 Jul 10;105(5):593-600
12740905
Cancer Res. 1997 Mar 15;57(6):1007-12
9067260
EMBO J. 1998 Feb 2;17(3):706-18
9450996
Nat Genet. 1995 Nov;11(3):294-300
7581453
EMBO J. 2000 Mar 1;19(5):931-41
10698935
EMBO J. 1995 Nov 15;14(22):5579-88
8521815
Cell. 1996 Jun 14;85(6):817-27
8681377
Nat Med. 2001 Mar;7(3):259
11231598
J Cell Biol. 1998 Jun 1;141(5):1243-53
9606215
Science. 1996 Nov 22;274(5291):1363-6
8910274
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6307-12
11353862
J Immunother Emphasis Tumor Immunol. 1993 Oct;14(3):234-41
7507710
Cell. 2003 Jul 25;114(2):181-90
12887920
J Biol Chem. 1999 Mar 19;274(12):7987-92
10075697
J Invest Dermatol. 1997 Feb;108(2):215-9
9008237
Int J Oncol. 2003 Jun;22(6):1375-81
12739008
Nature. 1998 Mar 19;392(6673):296-300
9521326
Blood. 2001 Aug 15;98(4):913-24
11493433
Proc Natl Acad Sci U S A. 2001 Nov 20;98 (24):13884-8
11717445
Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8104-9
10393955
Blood. 2000 Dec 1;96(12):3900-6
11090076
J Biol Chem. 2001 Dec 7;276(49):46639-46
11583996
J Biol Chem. 2001 Aug 10;276(32):29815-8
11390402
J Biol Chem. 2003 Oct 24;278(43):41585-8
12954630
Leukemia. 1999 Nov;13(11):1854-8
10557062
Nat Med. 2001 Jun;7(6):680-6
11385504
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5211-6
12702765
J Natl Cancer Inst. 1997 Jun 4;89(11):783-9
9182976
Blood. 1999 Nov 1;94(9):3135-40
10556200
Nature. 1998 Apr 30;392(6679):941-5
9582077
J Immunol. 2000 Feb 1;164(3):1236-42
10640736